LATEST ARTICLES

Rutgers Cancer Institute of New Jersey appoints immunotherapy chief

January 16, 2021 1 min read ...

COBRA Study to Test ctDNA as Biomarker for Adjuvant Chemotherapy Benefit in Colon Cancer

The NRG-GI005 (COBRA) study is the first phase 3 trial to test circulating tumor DNA (ctDNA) as a predictive biomarker for adjuvant chemotherapy benefit in patients with resected colon cancer and is actively accruing patients across all United States and Canadian cooperative groups, according to a poster presented at the 2021 Gastrointestinal Cancers Symposium....

Esophageal cancer patients show abundance of oral pathogens

IMAGE: In the dental plaque samples, the prevalence of all bacteria, with the exception of F. nucleatum, was significantly higher in the test group versus the control group. The pie charts... view more  Credit: Department of...

Publication of a Health Economic Analysis Demonstrates IsoPSA® Significantly Reduces Unnecessary Prostate Cancer Biopsies and Costs | Business

Publication of a Health Economic Analysis Demonstrates IsoPSA® Significantly Reduces Unnecessary Prostate Cancer Biopsies and Costs | Business | valdostadailytimes.com We recognize you...

Coffee Might Help Ward Off Prostate Cancer – Consumer Health News

TUESDAY, JAN. 12, 2021 (HealthDay News) -- A cup of java may not be a bad idea for men's health: Drinking lots of coffee may reduce their risk of prostate cancer, researchers report.The investigators analyzed data from 16 studies conducted around the world. Together, the studies involved more than a million men, about 58,000...